PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.31%
R&D reduction while Biotechnology median is 0.00%. Seth Klarman would investigate competitive implications.
-49.44%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
3.87%
Other expenses change of 3.87% versus flat Biotechnology costs. Walter Schloss would verify efficiency.
-37.34%
Operating expenses reduction while Biotechnology median is 0.49%. Seth Klarman would investigate advantages.
-37.34%
Total costs reduction while Biotechnology median is 0.34%. Seth Klarman would investigate advantages.
-62.14%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
3.87%
D&A change of 3.87% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
47.24%
EBITDA change of 47.24% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
37.34%
Income change of 37.34% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
1271.24%
Other expenses change of 1271.24% versus flat Biotechnology. Walter Schloss would verify control.
47.13%
Income change of 47.13% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-62.14%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
47.13%
Net income growth exceeding 1.5x Biotechnology median of 0.48%. Joel Greenblatt would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
50.90%
EPS growth exceeding 1.5x Biotechnology median of 5.32%. Joel Greenblatt would investigate advantages.
52.86%
Diluted EPS growth exceeding 1.5x Biotechnology median of 5.80%. Joel Greenblatt would investigate advantages.
7.67%
Share count reduction below 50% of Biotechnology median of 0.43%. Jim Chanos would check for issues.
12.32%
Diluted share reduction below 50% of Biotechnology median of 0.47%. Jim Chanos would check for issues.